Pancreatic Cancer Research

ResearcherShandong UniversityActive in the last 2 years

Xiaoyan Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-4283-8290; OpenAlex author ID A5100324653. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

  1. Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis. Co-author DOI 10.4240/wjgs.v16.i3.921↗
  2. Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28. Co-author DOI 10.1038/s41416-023-02313-y↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yue Yu · 1 shared paper, 2024 · strength 0.36
  2. J J Li · 1 shared paper, 2023 · strength 0.16
  3. Jie Gao · 1 shared paper, 2023 · strength 0.16
  4. Shujun Zhang · 1 shared paper, 2023 · strength 0.16
  5. Guoying Dong · 1 shared paper, 2023 · strength 0.16
  6. Chuanxin Wang · 1 shared paper, 2023 · strength 0.16
  7. Hanxiang Zhan · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.